A clinical trial to study the effect of G-CSF in sepsis associated immunosupression

INTERVENTION: Intervention1: EFfficacy of G‐CSF in sepsis associated immunosupression.: G‐CSF will be given for 7days, Dose:‐4microgram/kg/day s/c. drug will be stopped if TLC30,000/mm3. Subsequent management will be guided by unit protocol. Control Intervention1: Not applicable: Not applicable CONDITION: Health Condition 1: R098‐ Other specified symptoms and signsinvolving the circulatory and respiratory systems PRIMARY OUTCOME: As per picu record @SSH mortality among IPMOF is 63%. Mortality is defined as death within 28days of PICU stay. Reduction in mortality from 63% among IPMOF to 33%Timepoint: 7days,14days and at 28days during hospital stay SECONDARY OUTCOME: Differences in following parameters between 2 groups at various time points during hospitalisation ,organ failure inde XIL‐6,IL‐8 , TNF alpha and nosocomial infectionTimepoint: During admitted in picu INCLUSION CRITERIA: Multi‐organ failure more than or equal to 2 systems and persisting for 3days